Polycythemia Vera - Pipeline Review, H2 2017

Published: Aug, 2017 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides an overview of the Polycythemia Vera (Oncology) pipeline landscape.

Polycythemia Vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness and excessive sweating. The risk of polycythemia vera increases with age. Treatment includes alkylating agents.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycythemia Vera - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 3, 3 and 2 respectively.

Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycythemia Vera (Oncology).
- The pipeline guide reviews pipeline therapeutics for Polycythemia Vera (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycythemia Vera (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycythemia Vera (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycythemia Vera (Oncology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycythemia Vera (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycythemia Vera (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Figures
Introduction
Global Markets Direct Report Coverage
Polycythemia Vera - Overview
Polycythemia Vera - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Polycythemia Vera - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycythemia Vera - Companies Involved in Therapeutics Development
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
Galena Biopharma Inc
Gilead Sciences Inc
Italfarmaco SpA
Nerviano Medical Sciences Srl
PharmaEssentia Corp
Polycythemia Vera - Drug Profiles
anagrelide hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
givinostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idasanutlin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
idelalisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
peginterferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ropeginterferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycythemia Vera - Dormant Projects
Polycythemia Vera - Discontinued Products
Polycythemia Vera - Product Development Milestones
Featured News & Press Releases
Jun 25, 2017: AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
Mar 14, 2017: AOP Orphan Pharmaceuticals announces start of EMA marketing authorization application procedure for Ropeginterferon alfa-2b in Polycythemia Vera
Dec 05, 2016: AOP Orphan and PharmaEssentia Announce Pivotal Phase III results for Ropeginterferon alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2016
Nov 28, 2016: PharmaEssentia Announces Phase III PROUD-PV Study Results to be Presented at ASH Annual Meeting Oral Presentation
Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan
May 09, 2016: Merganser Biotech Announces Issuance of U.S. Patent 9,315,545 Covering Development Compound M012
May 06, 2016: Drug-like Compound Shows Promise in Treating Two Blood Diseases
Dec 08, 2015: Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 06, 2015: Galena Biopharma to Present Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology Annual Meeting and Exposition
Mar 05, 2015: AOP Orphan Pharmaceuticals announces progress of pivotal phase III trial PROUD-PV applying Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for treatment of Polycythemia Vera
Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial
Oct 10, 2013: AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV of Novel Mono-Pegylated Interferon Alpha 2b for the Treatment of Polycythemia Vera
Dec 10, 2012: AOP Orphan Pharma Reports Positive Phase II Data Of New Mono-pegylated Interferon Alpha 2b For Treatment Of Polycythemia Vera
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Polycythemia Vera, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Polycythemia Vera - Pipeline by Bristol-Myers Squibb Company, H2 2017
Polycythemia Vera - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Polycythemia Vera - Pipeline by Galena Biopharma Inc, H2 2017
Polycythemia Vera - Pipeline by Gilead Sciences Inc, H2 2017
Polycythemia Vera - Pipeline by Italfarmaco SpA, H2 2017
Polycythemia Vera - Pipeline by Nerviano Medical Sciences Srl, H2 2017
Polycythemia Vera - Pipeline by PharmaEssentia Corp, H2 2017
Polycythemia Vera - Dormant Projects, H2 2017
Polycythemia Vera - Discontinued Products, H2 2017